Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products.
No risks detected for 6ML from our risk checks.
Exceptional growth potential with flawless balance sheet.
Share Price & News
How has Molecular Partners's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6ML has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 6ML underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: 6ML underperformed the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is Molecular Partners's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Molecular Partners undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6ML's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 6ML's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 6ML is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 6ML is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6ML's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6ML is overvalued based on its PB Ratio (4.6x) compared to the DE Biotechs industry average (3.4x).
How is Molecular Partners forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6ML is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: 6ML is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6ML's is expected to become profitable in the next 3 years.
Revenue vs Market: 6ML's revenue (30.4% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: 6ML's revenue (30.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6ML's Return on Equity is forecast to be high in 3 years time (26.6%)
How has Molecular Partners performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6ML is currently unprofitable.
Growing Profit Margin: 6ML is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6ML is unprofitable, and losses have increased over the past 5 years at a rate of -45% per year.
Accelerating Growth: Unable to compare 6ML's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6ML is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: 6ML has a negative Return on Equity (-48.75%), as it is currently unprofitable.
How is Molecular Partners's financial position?
Financial Position Analysis
Short Term Liabilities: 6ML's short term assets (CHF129.5M) exceed its short term liabilities (CHF34.5M).
Long Term Liabilities: 6ML's short term assets (CHF129.5M) exceed its long term liabilities (CHF22.3M).
Debt to Equity History and Analysis
Debt Level: 6ML is debt free.
Reducing Debt: 6ML has not had any debt for past 5 years.
Inventory Level: 6ML has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 6ML's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 6ML has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 6ML is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -11.8% per year.
What is Molecular Partners's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6ML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 6ML's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6ML's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6ML's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6ML's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Patrick Amstutz (44yo)
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting C ...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD918.08K) is about average for companies of similar size in the German market ($USD817.80K).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
|Co-Founder||15.67yrs||no data||3.51% CHF11.7m|
|CFO & Member of Management Board||12.42yrs||no data||1.1% CHF3.7m|
|Chief Medical Officer & Member of Management Board||no data||no data||no data|
|Vice President of Technology||no data||no data||no data|
|Vice President of Finance||no data||no data||no data|
|General Counsel||3.17yrs||no data||no data|
|Vice President of Human Resources||0.42yr||no data||no data|
|Executive Officer||no data||no data||no data|
|Senior Vice President of Development||0.42yr||no data||no data|
Experienced Management: 6ML's management team is considered experienced (3 years average tenure).
|Non Executive Director||5.67yrs||CHF95.00k||0.0099% CHF32.9k|
|Vice-Chairman of the Board of Directors||1.5yrs||CHF98.00k||0.0099% CHF32.9k|
|Non Executive Director||10.67yrs||CHF103.00k||0.0099% CHF32.9k|
|Non Executive Director||12.67yrs||CHF106.00k||0.010% CHF33.1k|
|Chairman of the Board||1.42yrs||CHF305.00k||no data|
Experienced Board: 6ML's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Molecular Partners AG's company bio, employee growth, exchange listings and data sources
- Name: Molecular Partners AG
- Ticker: 6ML
- Exchange: DB
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF360.544m
- Listing Market Cap: CHF332.464m
- Shares outstanding: 21.38m
- Website: https://www.molecularpartners.com
Number of Employees
- Molecular Partners AG
- Wagistrasse 14
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MOLN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Nov 2014|
|0QXX||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Nov 2014|
|6ML||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Nov 2014|
|MLLC.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Nov 2014|
Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema diseases, as well as on a partnered pipeline that includes novel approaches to the treatment of severe ocular diseases. The company also develops MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc.; Janssen Biotech, Inc.; and Amgen SA. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/25 22:29|
|End of Day Share Price||2019/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.